# ALF-ONE : ALFuzosin ONcE Daily

> **NCT00280605** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 200 (—)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Alfuzosin

## Key facts

- **NCT ID:** NCT00280605
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 200 (—)
- **Last updated:** 2010-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280605, "ALF-ONE : ALFuzosin ONcE Daily". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00280605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*